[HTML][HTML] Early diagnosis of pancreatic cancer: What strategies to avoid a foretold catastrophe
V Tonini, M Zanni - World Journal of Gastroenterology, 2022 - ncbi.nlm.nih.gov
While great strides in improving survival rates have been made for most cancers in recent
years, pancreatic ductal adenocarcinoma (PDAC) remains one of the solid tumors with the …
years, pancreatic ductal adenocarcinoma (PDAC) remains one of the solid tumors with the …
[HTML][HTML] Recent pre-clinical advancements in nuclear medicine: pioneering the path to a limitless future
W Echavidre, D Fagret, M Faraggi, V Picco… - Cancers, 2023 - mdpi.com
Simple Summary This review summarizes recent advances in the nuclear medicine
theranostic approach. It covers the repurposing of historical radiotracers for new indications …
theranostic approach. It covers the repurposing of historical radiotracers for new indications …
Interrogating the Theranostic Capacity of a MUC16-Targeted Antibody for Ovarian Cancer
KN Mack, ZV Samuels, LM Carter… - Journal of Nuclear …, 2024 - Soc Nuclear Med
Aberrantly expressed glycans on mucins such as mucin-16 (MUC16) are implicated in the
biology that promotes ovarian cancer (OC) malignancy. Here, we investigated the …
biology that promotes ovarian cancer (OC) malignancy. Here, we investigated the …
[HTML][HTML] Highly selective targeting of pancreatic cancer in the liver with a near-infrared anti-MUC5AC probe in a PDOX mouse model: a proof-of-concept study
Accurately identifying metastatic disease is critical to directing the appropriate treatment in
pancreatic cancer. Mucin 5AC is overexpressed in pancreatic cancer but absent in normal …
pancreatic cancer. Mucin 5AC is overexpressed in pancreatic cancer but absent in normal …
Antibody-Based Theranostics in Ovarian Cancer: Targeting MUC16 for Diagnosis and Radioimmunotherapy
KN Mack - 2023 - search.proquest.com
Ovarian cancer causes more deaths than any other gynecological malignancy, with a five-
year relative survival rate of 30% for patients diagnosed at advanced stages. There is a …
year relative survival rate of 30% for patients diagnosed at advanced stages. There is a …
Clinical Significance and Levels of NLRP3, MUC5AC, and MUC5B in Asthma
Y Yao, S Li, J Zhou, Y Tian, J Zhang… - Journal of Clinical …, 2023 - ojs.bbwpublisher.com
Objective: To explore the role of NLRP3 in mucus hypersecretion in asthmatic patients.
Methods: From January 2020 to June 2022, 90 patients with asthma and 60 healthy patients …
Methods: From January 2020 to June 2022, 90 patients with asthma and 60 healthy patients …